Premium
Clinical and angiographic follow‐up after coronary drug‐eluting and bare metal stent implantation. Do drug‐eluting stents hold the promise?
Author(s) -
JENSEN J.,
LAGERQVIST B.,
AASA M.,
SÄREV T.,
NILSSON T.,
TORNVALL P.
Publication year - 2006
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.2006.01669.x
Subject(s) - medicine , restenosis , conventional pci , percutaneous coronary intervention , cardiology , stent , drug eluting stent , bare metal stent , angioplasty , clinical endpoint , surgery , clinical trial , myocardial infarction
. Objectives. To investigate the influence of drug‐eluting stent (DES) implantation on clinical and angiographic restenosis. Design. Registry study of data from the Swedish Coronary Angiography and Angioplasty Registry with a coronary angiographic substudy. Setting. Multi‐centre study. Subjects. During October 2002 to May 2004 a total of 23 590 percutaneous coronary intervention (PCI) procedures were performed at 25 hospitals. After selection, to achieve comparable groups, a total of 5068 patients of whom 4111 had a bare metal stent (BMS) implanted and 957 had a DES implanted, remained. End‐point in the registry follow‐up was >50% diameter restenosis at clinically driven reangiography within 12 months after index PCI. The primary end‐point in the angiographic substudy was late loss in patients’ DES at 6‐month angiographic follow‐up. Results. The rate of clinically driven restenosis, within 12 months, in patients receiving DES was less (3.9%) compared with those who received BMS (7.0%). In multivariate analysis the risk of clinical restenosis was one‐third for DES compared with BMS (HR 0.36, 95% CI 0.25–0.52). In the angiographic substudy late loss was 0.07 ± 0.53 mm (range −0.88 to 1.62). The amount of late loss was related to the presence of diabetes mellitus or not (0.19 ± 0.45 mm vs. −0.12 ± 0.58 mm), and lack of postdilatation of the stent or not (0.23 ± 0.51 mm vs. −0.09 ± 0.50 mm). Conclusions. The use of DES in the Swedish ‘real world’ is effective in reducing the clinically driven restenosis rate, when compared with patients with BMS treatment. In the angiographic follow‐up the average late loss was as low as observed in recent randomized multi‐centre trials.